Commonwealth of Pennsylvania Public School Empls Retrmt SYS Has $331,000 Position in Mallinckrodt PLC (MNK)
Commonwealth of Pennsylvania Public School Empls Retrmt SYS cut its holdings in Mallinckrodt PLC (NYSE:MNK) by 5.0% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 7,381 shares of the company’s stock after selling 391 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS’s holdings in Mallinckrodt PLC were worth $331,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. State of Tennessee Treasury Department boosted its holdings in Mallinckrodt PLC by 42.0% in the 2nd quarter. State of Tennessee Treasury Department now owns 40,502 shares of the company’s stock worth $1,815,000 after buying an additional 11,984 shares during the period. Commerzbank Aktiengesellschaft FI boosted its holdings in Mallinckrodt PLC by 2.3% in the 2nd quarter. Commerzbank Aktiengesellschaft FI now owns 57,894 shares of the company’s stock worth $2,594,000 after buying an additional 1,286 shares during the period. Swiss National Bank boosted its holdings in Mallinckrodt PLC by 1.7% in the 2nd quarter. Swiss National Bank now owns 381,126 shares of the company’s stock worth $17,078,000 after buying an additional 6,200 shares during the period. Chicago Equity Partners LLC boosted its holdings in Mallinckrodt PLC by 5.0% in the 2nd quarter. Chicago Equity Partners LLC now owns 167,845 shares of the company’s stock worth $7,521,000 after buying an additional 7,990 shares during the period. Finally, OMERS ADMINISTRATION Corp bought a new position in Mallinckrodt PLC in the 2nd quarter worth approximately $260,000. 97.40% of the stock is owned by institutional investors.
In related news, insider Meredith B. Fischer bought 1,280 shares of the company’s stock in a transaction that occurred on Wednesday, August 30th. The stock was purchased at an average price of $39.63 per share, for a total transaction of $50,726.40. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.77% of the stock is currently owned by corporate insiders.
Shares of Mallinckrodt PLC (NYSE:MNK) opened at 34.83 on Friday. The stock’s 50 day moving average is $37.65 and its 200 day moving average is $42.88. Mallinckrodt PLC has a 52-week low of $33.61 and a 52-week high of $76.81. The stock’s market cap is $3.38 billion.
Mallinckrodt PLC (NYSE:MNK) last issued its earnings results on Tuesday, August 8th. The company reported $1.85 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.73 by $0.12. Mallinckrodt PLC had a net margin of 12.64% and a return on equity of 15.28%. The firm had revenue of $824.50 million during the quarter, compared to analyst estimates of $829.56 million. During the same quarter in the prior year, the business earned $2.03 earnings per share. Mallinckrodt PLC’s revenue for the quarter was down 4.9% on a year-over-year basis. Equities research analysts forecast that Mallinckrodt PLC will post $7.43 earnings per share for the current year.
MNK has been the subject of several analyst reports. Zacks Investment Research downgraded shares of Mallinckrodt PLC from a “hold” rating to a “sell” rating in a report on Tuesday, July 11th. UBS AG reaffirmed a “buy” rating and issued a $70.00 price objective on shares of Mallinckrodt PLC in a report on Wednesday, September 6th. Wells Fargo & Company reaffirmed an “outperform” rating and issued a $83.50 price objective on shares of Mallinckrodt PLC in a report on Wednesday, June 21st. ValuEngine downgraded shares of Mallinckrodt PLC from a “buy” rating to a “hold” rating in a report on Friday, September 1st. Finally, Jefferies Group LLC cut their price objective on shares of Mallinckrodt PLC from $70.00 to $60.00 and set a “buy” rating for the company in a report on Friday, August 25th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and fourteen have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $62.99.
Mallinckrodt PLC Company Profile
Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs.
Receive News & Ratings for Mallinckrodt PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt PLC and related companies with MarketBeat.com's FREE daily email newsletter.